ATC Group: G03GA06 Follitropin beta

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G03GA06 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G03 Sex hormones and modulators of the genital system
3 G03G Gonadotropins and other ovulation stimulants
4 G03GA Gonadotropins
5 G03GA06 Follitropin beta

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 75 [iU]

Active ingredients in G03GA06

Active Ingredient Description
Follitropin beta

Follitropin beta is a recombinant FSH. Follitropin beta can be used to stimulate follicular development and steroid production in selected cases of disturbed gonadal function. Furthermore follitropin beta can be used to promote multiple follicular development in medically assisted reproduction programs.

Related product monographs

Title Information Source Document Type  
PUREGON Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Canada (CA)

Cyprus (CY)

Estonia (EE)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.